4 completed, 2 withdrawn, 1 active not recruiting, 1 recruiting. 8 Phase 2, 1 Phase 3.
By phase and status
Follow islatravir: new trials by email Literature Review of islatravir trials Research Report on islatravir
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) ISL, ULO, BIC/FTC/TAF - Human Immunodeficiency Virus Type 1 (HIV-1) Infection Phase 2 / Phase 3 Recruiting 570 2025-12-18 2026-11-04
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) ISL, ULO, BIC/FTC/TAF - Human Immunodeficiency Virus Type 1 (HIV-1) Infection Phase 2 Active not recruiting 150 2025-04-14 2025-10-16
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043) Islatravir, Placebo - Human Immunodeficiency Virus, HIV Phase 2 Withdrawn 2024-01-04 2023-11-24
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) Islatravir - Human Immunodeficiency Virus (HIV) Infections Phase 2 Withdrawn 2022-10-17 2022-10-17
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] Islatravir, Ulonivirine, BIC/FTC/TAF - HIV-1 Infection Phase 2 Completed 161 2021-03-09 2026-01-26
Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028) DOR/ISL - HIV-1 Infection Phase 2 Completed 42 2020-11-26 2024-01-31
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) Islatravir, Placebo - HIV-1 Infection Phase 2 Completed 242 2019-09-19 2025-07-18
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) Islatravir, Placebo to Islatravir, Doravirine - HIV-1 Infection Phase 2 Completed 123 2017-11-27 2023-03-29
Conditions studied Acquired Immunodeficiency Syndrome (4) · Infections (3)
Sponsors Merck Sharp & Dohme LLC (8)
Countries United States (6) · France (3) · South Africa (3) · Chile (2) · Switzerland (2) · Argentina (1) · Australia (1) · Canada (1) · Guatemala (1) · Israel (1) · Italy (1) · Mexico (1) · Puerto Rico (1) · Russia (1) · Spain (1)
Results publications PMID 33540481 , PMID 34000227 , PMID 35972855 , PMID 40260892 , PMID 40327547 , PMID 41789892
NIH funding 2019 (2) , 2017 (1) , 2025 (1)